[1] Glassroth J. Pulmonary disease due to nontuberculous mycobacteria. Chest, 2008; 133, 243-51. doi:  10.1378/chest.07-0358
[2] Halstrom S, Price P, Thomson R. Review: Environmental mycobacteria as a cause of human infection. Int J Mycobacteriol, 2015; 4, 81-91. doi:  10.1016/j.ijmyco.2015.03.002
[3] Moore JE, Kruijshaar ME, Ormerod LP, et al. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health, 2010; 10, 612. doi:  10.1186/1471-2458-10-612
[4] Shah NM, Davidson JA, Anderson LF, et al. Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007-2012. BMC Infect Dis, 2016; 16, 195. doi:  10.1186/s12879-016-1521-3
[5] Wang L, Cheng S, Chen M, et al. The fifth national tuberculosis epidemiological survey in 2010. Chin J Antituber, 2012; 34, 485-508. (In Chinese)
[6] Wang L, Zhang H, Ruan Y, et al. Tuberculosis prevalence in China, 1990-2010: a longitudinal analysis of national survey data. Lancet, 2014; 383, 2057-64. doi:  10.1016/S0140-6736(13)62639-2
[7] Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev, 2002; 15, 716-46. doi:  10.1128/CMR.15.4.716-746.2002
[8] Kang YA, Koh WJ. Antibiotic treatment for nontuberculous mycobacterial lung disease. Expert Rev Respir Med, 2016; 10, 557-68. doi:  10.1586/17476348.2016.1165611
[9] Mougari F, Loiseau J, Veziris N, et al. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. J Antimicrob Chemother, 2017; 72, 1669-77. doi:  10.1093/jac/dkx021
[10] Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc, 1999; 74, 613-34. doi:  10.4065/74.6.613
[11] Fyfe C, Grossman TH, Kerstein K, et al. Resistance to macrolide antibiotics in public health pathogens. Cold Spring Harb Perspect Med, 2016; 6, a025395. http://cn.bing.com/academic/profile?id=b8d4ab56feba8aefee5ffc3d2e4930c4&encoded=0&v=paper_preview&mkt=zh-cn
[12] Nasiri MJ, Haeili M, Ghazi M, et al. New insights in to the intrinsic and acquired drug resistance mechanisms in mycobacteria. Front Microbiol, 2017; 8, 681. doi:  10.3389/fmicb.2017.00681
[13] Nash KA, Andini N, Zhang Y, et al. Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob Agents Chemother, 2006; 50, 3476-8. doi:  10.1128/AAC.00402-06
[14] Zhang YY, Li YB, Huang MX, et al. Novel species including Mycobacterium fukienense sp. is found from tuberculosis patients in Fujian Province, China, using phylogenetic analysis of Mycobacterium chelonae/abscessus complex. Biomed Environ Sci, 2013; 26, 894-901. http://kns.cnki.net/KCMS/detail/detail.aspx?filename=swyx201311004&dbname=CJFD&dbcode=CJFQ
[15] Nguyen L, Chinnapapagari S, Thompson CJ. FbpA-Dependent biosynthesis of trehalose dimycolate is required for the intrinsic multidrug resistance, cell wall structure, and colonial morphology of Mycobacterium smegmatis. J Bacteriol, 2005; 187, 6603-11. doi:  10.1128/JB.187.19.6603-6611.2005
[16] Braibant M, Gilot P, Content J. The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. FEMS Microbiol Rev, 2000; 24, 449-67. doi:  10.1111/j.1574-6976.2000.tb00550.x
[17] CLSI. Susceptibility testing of mycobacteria, Nocardiae, and other aerobic actinomycetes; approved standard—second edition. Wayne, PA; Clinical and Laboratory Standards Institute. 2011.
[18] Wallace RJ, Meier A, Brown BA, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother, 1996; 40, 1676-81. doi:  10.1164/rccm.200905-0704OC
[19] Bastian S, Veziris N, Roux AL, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother, 2011; 55, 775-81. doi:  10.1128/AAC.00861-10
[20] Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother, 2009; 53, 1367-76. doi:  10.1128/AAC.01275-08
[21] Kirst HA, Sides GD. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother, 1989; 33, 1419-22. doi:  10.1128/AAC.33.9.1419
[22] Hirama T, Shiono A, Egashira H, et al. PCR-based rapid identification system using bridged nucleic acids for detection of clarithromycin-resistant Mycobacterium avium-M. intracellulare Complex Isolates. J Clin Microbiol, 2016; 54, 699-704. doi:  10.1128/JCM.02954-15
[23] Foo H, van Hal S, Jelfs P, et al. Antimicrobial resistance in non-tuberculous mycobacteria in New South Wales, 2002-2008. Int J Antimicrob Agents, 2009; 34, 182-4. doi:  10.1016/j.ijantimicag.2009.01.013
[24] Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs, 1992; 44, 750-99. doi:  10.2165/00003495-199244050-00007
[25] Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med, 2012; 186, 917-25. doi:  10.1164/rccm.201111-2005OC
[26] Maurer FP, Castelberg C, Quiblier C, et al. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. J Antimicrob Chemother, 2014; 69, 1559-63. doi:  10.1093/jac/dku007
[27] Struillou L, Cohen Y, Lounis N, et al. Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. Antimicrob Agents Chemother, 1995; 39, 878-81. doi:  10.1128/AAC.39.4.878
[28] Sodemoto K, Shimada Y, Nishijima C, et al. Successful treatment of cutaneous Mycobacterium chelonae infection with roxithromycin. J Dermatol, 2007; 34, 846-8. doi:  10.1111/jde.2007.34.issue-12
[29] Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med, 2011; 183, 405-10. doi:  10.1164/rccm.201003-0395OC
[30] Esteban J, Martin-de-Hijas NZ, Garcia-Almeida D, et al. Prevalence of erm methylase genes in clinical isolates of non-pigmented, rapidly growing mycobacteria. Clin Microbiol Infect, 2009; 15, 919-23. doi:  10.1111/j.1469-0691.2009.02757.x
[31] Renvoise A, Bernard C, Veziris N, et al. Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare. J Clin Microbiol, 2014; 52, 4439-40. doi:  10.1128/JCM.02127-14
[32] van Ingen J, van der Laan T, Dekhuijzen R, et al. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents, 2010; 35, 169-73. doi:  10.1016/j.ijantimicag.2009.09.023
[33] Lee SH, Yoo HK, Kim SH, et al. The drug resistance profile of Mycobacterium abscessus group strains from Korea. Ann Lab Med, 2014; 34, 31-7. doi:  10.3343/alm.2014.34.1.31